FDA Approval of New Drug Candidate in Phase 3 Trials
Resolves: Successful FDA approval of a new drug indicated for a specific condition.
sec_filing· Regulatory Approval
FDA Approval of New Drug Candidate in Phase 3 Trials
Market overview
Derived from Jaguar Health, Inc. (JAGX) (CIK 0001585608) 10-K filing analysis
Regulatory Approval prediction market
- Implied probability (Yes)
- 60%
- Closes
- 2027-12-31
About this prediction
Resolution criteria
Successful FDA approval of a new drug indicated for a specific condition.
More Regulatory Approval markets
- FDA Approval Anticipation for AEMD Products — 40% Yes
- Favorable Regulatory Outcome for Business Combination — 80% Yes
- Will the SEC declare the proxy statement effective by February 28, 2027? — 65% Yes
- New Product Regulatory Approval — 75% Yes
- Will CLCS receive FDA approval for any of its drug candidates in the next two years? — 40% Yes
- Will the divestiture close by Q1 2027? — 85% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…